{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:18:58Z","timestamp":1773220738441,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81901229"],"award-info":[{"award-number":["81901229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04679-x","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:38:42Z","timestamp":1770370722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers for satralizumab treatment in neuromyelitis optica spectrum disorders: a prospective case series"],"prefix":"10.1186","volume":"26","author":[{"given":"Shengfei","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haotian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yipeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"4679_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021;18:208. https:\/\/doi.org\/10.1186\/s12974-021-02249-1.","journal-title":"J Neuroinflammation"},{"key":"4679_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol. 2021;17:759\u201373. https:\/\/doi.org\/10.1038\/s41582-021-00568-8.","journal-title":"Nat Rev Neurol"},{"key":"4679_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100010","volume":"1","author":"D-C Tian","year":"2020","unstructured":"Tian D-C, Zhang C, Yuan M, et al. Incidence of multiple sclerosis in China: a nationwide hospital-based study. Lancet Reg Health West Pac. 2020;1:100010. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100010.","journal-title":"Lancet Reg Health West Pac"},{"key":"4679_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","volume":"80","author":"Y-A Heo","year":"2020","unstructured":"Heo Y-A. Satralizumab: first approval. Drugs. 2020;80:1477\u201382. https:\/\/doi.org\/10.1007\/s40265-020-01380-2.","journal-title":"Drugs"},{"key":"4679_CR5","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1901747.","journal-title":"N Engl J Med"},{"key":"4679_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19:402\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(20)30078-8.","journal-title":"Lancet Neurol"},{"key":"4679_CR7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis. Neurology. 1983;33:1444\u20131444. https:\/\/doi.org\/10.1212\/WNL.33.11.1444.","journal-title":"Neurology"},{"key":"4679_CR8","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1007\/s00415-024-12382-5","volume":"271","author":"R Wang","year":"2024","unstructured":"Wang R, Sun D, Wang X, et al. Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder. J Neurol. 2024;271:4503\u201312. https:\/\/doi.org\/10.1007\/s00415-024-12382-5.","journal-title":"J Neurol"},{"key":"4679_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3969\/j.issn.1673-5374.2013.08.005","volume":"8","author":"M Li","year":"2013","unstructured":"Li M, Su W, Wang J, et al. Detection of anti-aquaporin-4 autoantibodies in the Sera of Chinese neuromyelitis Optica patients. Neural Regen Res. 2013;8:708\u201313. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2013.08.005.","journal-title":"Neural Regen Res"},{"key":"4679_CR10","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3760\/cma.j.issn.0376-2491.2018.21.008","volume":"98","author":"X Huang","year":"2018","unstructured":"Huang X, Xu FF, Qian HR, et al. [Clinical presentations of neuromyelitis Optica spectrum disorders with ultra-longitudinally extensive transverse myelitis]. Zhonghua Yi Xue Za Zhi. 2018;98:1658\u201363. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2018.21.008.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"4679_CR11","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131:3072\u201380. https:\/\/doi.org\/10.1093\/brain\/awn240.","journal-title":"Brain"},{"key":"4679_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13137-6","volume":"272","author":"Z Wang","year":"2025","unstructured":"Wang Z, Tan H, Huang W, et al. Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder. J Neurol. 2025;272:403. https:\/\/doi.org\/10.1007\/s00415-025-13137-6.","journal-title":"J Neurol"},{"key":"4679_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/ana.26623","volume":"93","author":"H Yin","year":"2023","unstructured":"Yin H, Wang Y, Liu M, et al. Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis optica spectrum disorder treated with immunosuppressants. Ann Neurol. 2023;93:1069\u201381. https:\/\/doi.org\/10.1002\/ana.26623.","journal-title":"Ann Neurol"},{"key":"4679_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000727","volume":"7","author":"J Jitprapaikulsan","year":"2020","unstructured":"Jitprapaikulsan J, Fryer JP, Majed M, et al. Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2020;7:e727. https:\/\/doi.org\/10.1212\/NXI.0000000000000727.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4679_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2017.08.005","volume":"17","author":"RA Kessler","year":"2017","unstructured":"Kessler RA, Mealy MA, Jimenez-Arango JA, et al. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: a multicenter cohort study. Mult Scler Relat Disord. 2017;17:198\u2013201. https:\/\/doi.org\/10.1016\/j.msard.2017.08.005.","journal-title":"Mult Scler Relat Disord"},{"key":"4679_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02138-7","volume":"18","author":"P Schindler","year":"2021","unstructured":"Schindler P, Grittner U, Oechtering J, et al. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation. 2021;18:105. https:\/\/doi.org\/10.1186\/s12974-021-02138-7.","journal-title":"J Neuroinflammation"},{"key":"4679_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211054952","volume":"14","author":"T-X Zhang","year":"2021","unstructured":"Zhang T-X, Chen J-S, Du C, et al. Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord. 2021;14:17562864211054952. https:\/\/doi.org\/10.1177\/17562864211054952.","journal-title":"Ther Adv Neurol Disord"},{"key":"4679_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","volume":"94","author":"O Aktas","year":"2023","unstructured":"Aktas O, Hartung H-P, Smith MA, et al. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2023;94:757\u201368. https:\/\/doi.org\/10.1136\/jnnp-2022-330412.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4679_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720907","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Cui C, Lu Y, et al. Therapeutic response and possible biomarkers in acute attacks of neuromyelitis optica spectrum disorders: a prospective observational study. Front Immunol. 2021;12:720907. https:\/\/doi.org\/10.3389\/fimmu.2021.720907.","journal-title":"Front Immunol"},{"key":"4679_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13249-z","volume":"272","author":"R Wang","year":"2025","unstructured":"Wang R, Wang X, Sun D, et al. Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD. J Neurol. 2025;272:521. https:\/\/doi.org\/10.1007\/s00415-025-13249-z.","journal-title":"J Neurol"},{"key":"4679_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg8148","author":"W Jiang","year":"2023","unstructured":"Jiang W, Zhu F, Xu H, et al. CHI3L1 signaling impairs hippocampal neurogenesis and cognitive function in autoimmune-mediated neuroinflammation. Sci Adv. 2023. https:\/\/doi.org\/10.1126\/sciadv.adg8148.","journal-title":"Sci Adv"},{"key":"4679_CR22","doi-asserted-by":"publisher","unstructured":"Fissolo N, Benkert P, Sastre-Garriga J, et al. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023;jnnp\u20132023\u2013332251. https:\/\/doi.org\/10.1136\/jnnp-2023-332251.","DOI":"10.1136\/jnnp-2023-332251"},{"key":"4679_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578644","volume":"405","author":"S Miyake","year":"2025","unstructured":"Miyake S, Katsura Y, Baba M, et al. Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity. J Neuroimmunol. 2025;405:578644. https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578644.","journal-title":"J Neuroimmunol"},{"key":"4679_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02441-x","volume":"19","author":"PK West","year":"2022","unstructured":"West PK, McCorkindale AN, Guennewig B, et al. The cytokines interleukin-6 and interferon-\u03b1 induce distinct microglia phenotypes. J Neuroinflammation. 2022;19:96. https:\/\/doi.org\/10.1186\/s12974-022-02441-x.","journal-title":"J Neuroinflammation"},{"key":"4679_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02375-w","volume":"19","author":"Y Hoshino","year":"2022","unstructured":"Hoshino Y, Noto D, Sano S, et al. Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder. J Neuroinflammation. 2022;19:6. https:\/\/doi.org\/10.1186\/s12974-021-02375-w.","journal-title":"J Neuroinflammation"},{"key":"4679_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255533","volume":"14","author":"E Grebenciucova","year":"2023","unstructured":"Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023;14:1255533. https:\/\/doi.org\/10.3389\/fimmu.2023.1255533.","journal-title":"Front Immunol"},{"key":"4679_CR27","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1038\/s41467-022-33787-8","volume":"13","author":"RY-H Cheng","year":"2022","unstructured":"Cheng RY-H, Hung KL, Zhang T, et al. Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo. Nat Commun. 2022;13:6110. https:\/\/doi.org\/10.1038\/s41467-022-33787-8.","journal-title":"Nat Commun"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04679-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:39:37Z","timestamp":1773142777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04679-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4679"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04679-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (II2023-080-01) and conducted in accordance with the Declaration of Helsinki. All participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of this manuscript have approved its publication. Since the manuscript does not include any personal data from individuals, consent for the publication of personal information is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}